Tag : ATOGEPANT

CONFERENCE UPDATE

Interim analysis of a long-term safety and efficacy extension study of atogepant in episodic and chronic migraine prevention
Atogepant is an oral anti-migraine drug that blocks the calcitonin gene-related peptide (CGRP) receptor.1 It was previously evaluated in the phase 3, randomized, double-blind, placebo-controlled trials ELEVATE and PROGRESS for the prevention of episodic migraine (EM) or chronic migraine (CM), respectively.